Affamed Therapeutics Receives Approval for Phase 3 Clinical Trial of Dextenza in Mainland China for Ocular Inflammation and Pain Treatment
Affamed Therapeutics Receives Approval for Phase 3 Clinical Trial of Dextenza in Mainland China for Ocular Inflammation and Pain Treatment SHANGHAI, April 17, 2023 /PRNewswire/ — AffaMed Therapeutics Overview AffaMed Therapeutics (“AffaMed”) is a global biotechnology company that is dedicated to developing and commercializing transformative pharmaceutical, digital, and surgical products. The company focuses on addressing…